Skip directly to content


2019 | 2018 | 2017 |2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992

A Landscape Analysis of HIV Cure-Related Clinical Trials in 2018
November 4, 2019
– In August 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing, in order to obtain more detailed information about the current landscape of HIV cure-related clinical research.

Activist Guide to Hepatitis C Virus Diagnostics
October 31, 2019
– This new publication and training curriculum aim to provide a deeper focus on diagnosis, with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.

Ensuring Treatment for Children with Orphan Diseases: Ending Exemptions from the Pediatric Research Equity Act (PREA)
August 27, 2019 – This policy brief was developed by TAG and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), and it details how children with TB are affected by the pediatric research exemption for orphan drugs.

New HCV Fact Sheets
June 20, 2019 – We updated our factsheets on sofosbuvir/daclatasvir and Mavyret, and each one is available in English and in Spanish.

Nothing About Us Without Us – TAGline, May 2019
May 2, 2019 – This TAGline is all about the importance of community engagement in research to end the epidemics of HIV, HCV, and TB. As this edition’s cover shows, protestors at the “Storm the NIH” demonstration and die-in in May 1990 demanded political will and funding for research, and equitable access to treatment for HIV.

An Activist’s Guide to Rifapentine for the Treatment of TB Infection
April 30, 2019 – Our publication, An Activist’s Guide to Rifapentine, details important efficacy, safety, and access information on rifapentine, a game-changing drug for treating tuberculosis (TB) infection in order to prevent active TB disease. Rifapentine is the backbone of newer regimens for preventing TB that are shorter and easier to complete than the older standard of care (called isoniazid preventive therapy).

TB LAM Testing Briefs
April 10, 2019 – Our two briefs, The LAM Test: Ensuring Scaled-Up, Expanded TB LAM Testing for People Living With Advanced HIV for Country Programs and The LAM Test: Ensuring Scaled-Up, Expanded TB LAM Testing for People Living With Advanced HIV for Donors, offer scientific evidence of the benefits of TB LAM testing, share an analysis of PEPFAR and Global Fund grants for the inclusion of TB LAM testing, and outline potential steps that countries and donors can take to make sure national TB programs can easily access this life-saving test.

New HCV Fact Sheets
March 29, 2019 – We just posted factsheets on sofosbuvir/daclatasvir and Mavyret, and each one is available in English and in Spanish.

Gene Editing in HIV Research
March 21, 2019 – The purpose of this issue brief is to provide background information on gene editing in HIV research, and context for the news about researcher He Jiankui’s misuse of the technology to alter embryos (Chinese authorities have since declared He's experiments illegal, the trial has been stopped, and investigations are ongoing).

Pipeline for Gonorrhea, Chlamydia, and Syphilis
March 20, 2019 – A new report on the sexually transmitted infection (STI) treatment and prevention research “pipeline” points to serious gaps in the development of new tools to address a growing epidemic in the U.S.  The report, released today by TAG and supported by NCSD, provides an assessment of the current research pipeline and calls for a major new investment in STI research.

EATAN HIV/AIDS & Hepatitis C Community Summit Report
February 25, 2019 – In July, 2018, The European African Treatment Advocates Network (EATAN), in conjunction with TAG, held a Community Summit in Amsterdam, the Netherlands. EATAN focuses on supporting the medical and social needs of African migrant populations with HIV, HCV and other chronic health conditions.

Closing the Gap in Tuberculosis Research and Development Funding Briefs
February 20, 2019
 – In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.

December 2018 TAG Update
December 13, 2018 – We accomplished some great things in 2018, and they were made possible by our generous donors. Download your own copy of TAG Update to read all about them.

Fall, 2018 TAGline: Bringing Down the House on Intellectual Property and Access
December 11, 2018 – This issue of TAGline dives deep into the rhetoric and realities of intellectual property  (IP)  protections  and  the current wave of political shenanigans on critical drugs, surfacing the fundamental lies and vested interests that deny medication to those in need in the United States and around the world.

Tuberculosis Research Funding Trends 2005 – 2017
December 3, 2018 – Global funding for tuberculosis (TB) research climbed to a previously unreported high of USD $772 million in 2017, according to a report released today by Treatment Action Group (TAG) and the United Nations-hosted Stop TB Partnership.

Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults
November 14, 2018
– The research effort to develop a cure for HIV infection includes clinical studies in which people with HIV are asked to temporarily interrupt antiretroviral therapy. Analytical treatment interruptions (ATIs), as they are called, go against the current standard of care and may pose risks. TAG has generated an updated set of community recommendations on the use of ATIs in research, with the aim of contributing to the discussion regarding maximizing safety and minimizing risk for participants.

Reality Check: The Price of Bedaquiline
October 16, 2018 – Bedaquiline is now recommended as a core part of drug-resistant TB treatment, but price is a major concern to ensuring all who need treatment with bedaquiline receive it. The public has made significant investments in the development and introduction of bedaquiline, which should be reflected in the price.

An Activists Guide to Bedaquiline
October 5, 2018 – This guide — updated from the original version put out by Treatment Action Group in 2013 — summarizes updated efficacy, safety, and access information about bedaquiline, an essential medication in the treatment of multidrug-resistant TB (MDR-TB).

Funding for TB Research: Recent Momentum Must Inspire Bold Commitments
September 24, 2018 – In advance of the first-ever United Nations High-Level Meeting on Tuberculosis (TB), a new brief from Treatment Action Group (TAG) — Funding for TB Research: Recent Momentum Must Inspire Bold Commitments — shows that global funding for TB research and development (R&D) reached a new high of USD $767.8 million in 2017.